Notice Pursuant to the National Cooperative Research and Production Act of 1993 - Biopharmaceutical Manufacturing Preparedness Consortium
AI-generated summary for informational purposes only. Not legal advice. See the original source for the authoritative text.
The U.S. Department of Justice Antitrust Division published a notice on March 26, 2026, regarding the Biopharmaceutical Manufacturing Preparedness Consortium (BIOMAP-CONSORTIUM). On October 8, 2025, the consortium filed notifications disclosing the addition of 39 new member organizations from the United States, Israel, France, Germany, Belgium, and Canada. These additions qualify the venture for protections under the National Cooperative Research and Production Act of 1993, which limits antitrust plaintiffs to recovering only actual damages under specified circumstances. The consortium's membership remains open and it plans to file further notifications for any future changes. The original notification was filed on January 5, 2024, with the most recent prior update on July 24, 2025.
AI-generated summary. May contain errors. Refer to official sources for legal decisions.
Key Changes
- Addition of 39 new member companies and organizations on October 8, 2025
- Members added from USA, Israel, France, Germany, Belgium and Canada
- Extension of antitrust protections limiting recovery to actual damages
+ 3 more changes with Pro
Obligations
What this law requires
Maintain open membership in the group research project and allow new parties to join
File written notifications simultaneously with the Attorney General and the Federal Trade Commission disclosing any changes in consortium membership
Disclose all changes in membership to maintain eligibility for antitrust protections under the National Cooperative Research and Production Act of 1993
File additional written notifications for all future changes in consortium membership